Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer

Background The management of estrogen receptor positive (ER+)/HER2− and lymph node (LN) negative breast cancers can be influenced by Oncotype DX recurrence score (RS) in the USA. However, the benefit of RS in T1 tumors (≤ 1 cm) is not clear. Methods We retrieved 199 T1 ER+/HER2−/LN− breast cancer di...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2022-04, Vol.192 (3), p.509-516
Hauptverfasser:	Nguyen, Thi Truc Anh, Postlewait, Lauren M., Zhang, Chao, Meisel, Jane L., O’Regan, Ruth, Badve, Sunil, Kalinsky, Kevin, Li, Xiaoxian
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers, Tumor - genetics Bone tumors Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cancer Cancer research Chemotherapy Chemotherapy, Adjuvant Decision making Diagnosis ErbB-2 protein Estrogen Estrogen receptors Estrogens Female Humans Lymph nodes Lymphatic system Mediastinum Medicine Medicine & Public Health Metastases Metastasis Multivariate analysis Neoplasm Recurrence, Local - drug therapy Oncology Patients Phenols Preclinical Study Prognosis Receptor, ErbB-2 - genetics Receptors, Estrogen - genetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!